← REGULATORY CHANGES
FEDERAL REGISTER · NOTICEFebruary 16, 2024NOTICE — NO LEGAL EFFECT

Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Extension of Comment Period

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSNOTICE — NO LEGAL EFFECT
EFFECTIVE—
COMMENTS CLOSEMar 21, 2024 · closed
APPLIES TO · SPEQ TAGDrugBiologics
Document type
Notice
Agency
Health and Human Services Department
Published
February 16, 2024
Comments close
March 21, 2024
Document number
2024-03296
Docket
FDA-2023-D-5259
ABSTRACT

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice of availability that published in the Federal Register of December 22, 2023. In that notice, FDA requested comments on the draft guidance for industry entitled, "Master Protocols for Drug and Biological Product Development." The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.

Abstract as published in the Federal Register.

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →

That is what FDA published. A free account files it on your watchlist and sends one weekly email with whatever lands next.

Create a free account